Share chart Eterna Therapeutics Inc.
Extended chart
Simple chart
About Eterna Therapeutics Inc.
Eterna Therapeutics Inc., a preclinical-stage, biopharmaceutical company. The company offers Synthetic mRNA, ToRNAdo mRNA Delivery, mRNA Gene Editing, and mRNA Cell Reprogramming. It also develops therapies and medicines using gene-editing proteins and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. The company was formerly known as Brooklyn ImmunoTherapeutics, Inc. and changed its name to Eterna Therapeutics Inc. in October 2022. Eterna Therapeutics Inc. is based in Cambridge, Massachusetts.Main settings
| IPO date | 1992-10-19 |
|---|---|
| ISIN | US1140821000 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Сайт | link |
| Change price per day: | 0% (0.23) |
|---|---|
| Change price per week: | 0% (0.23) |
| Change price per month: | +9.52% (0.21) |
| Change price per 3 month: | -20.69% (0.29) |
| Change price per half year: | -46.51% (0.43) |
| Change price per year: | -87.43% (1.83) |
| Change price per 3 year: | -63.49% (0.63) |
| Change price per 5 year: | -78.5% (1.07) |
| Change price per year to date: | -17.86% (0.28) |
Grade
Underestimation
| Title | Value | Grade |
|---|---|---|
| P/S | 6.8 | 1 |
| P/BV | 2.33 | 6 |
| P/E | 0 | 0 |
Efficiency
| Title | Value | Grade |
|---|---|---|
| ROA, % | -163.74 | 0 |
| ROE, % | -2264.31 | 0 |
| ROIC, % | 0 | 0 |
Dividends
| Title | Value | Grade |
|---|---|---|
| Dividend yield | 0 | 0 |
| DSI | 0 | 0 |
| Average dividend growth | 0 | 0 |
Debt
| Title | Value | Grade |
|---|---|---|
| Debt/EBITDA | -0.0189 | 10 |
| Debt/Ratio | 0.1298 | 10 |
| Debt/Equity | 2.1 | 6 |
Growth impulse
| Title | Value | Grade |
|---|---|---|
| Yield Revenue, % | -97.5 | 0 |
| Yield Ebitda, % | 401.65 | 10 |
| Yield EPS, % | -7.55 | 0 |
Main owners
| Institutions | Volume | Share, % |
|---|---|---|
| Lake Street Advisors Group, LLC | 520 996 | 9.63 |
| Cypress Point Wealth Management, LLC | 94 375 | 1.74 |
| Naviter Wealth, LLC | 78 796 | 1.46 |
| Sippican Capital Advisors | 54 050 | 1 |
| Corient Private Wealth LLC | 50 398 | 0.93 |
| Vanguard Group Inc | 26 099 | 0.48 |
| Geode Capital Management, LLC | 22 488 | 0.42 |
| Blackrock Inc. | 15 619 | 0.29 |
| Baldwin Brothers, Inc. | 8 544 | 0.16 |
| Tower Research Capital LLC (TRC) | 4 409 | 0.08 |
Similar companies
P/E & P/BV
Company management
| Head | Job title | Payment | Year of birth |
|---|---|---|---|
| Ms. Sandra M. Gurrola | Principal Financial & Accounting Officer and Senior VP of Finance | 305.88k | 1967 (58 years) |
| Mr. Sanjeev Luther | CEO, President & Director | N/A | 1962 (63 years) |
| Ms. Dorothy J. Clarke | General Counsel & Director | N/A | 1966 (59 years) |
| Dr. Robert Hamilton Pierce M.D. | Chief Scientific Officer | 1964 (61 year) |
About company
Address: United States, Cambridge. MA, 1035 Cambridge Street - Open in google maps, Open in yandex maps
Website: https://eternatx.com
Website: https://eternatx.com
